TCGA-HD-7832-01A-11R-2132-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.740
- E2F_TARGETS+0.720
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.590
- INTERFERON_GAMMA_RESPONSE+0.560
- MYC_TARGETS_V1+0.560
- MITOTIC_SPINDLE+0.450
- MTORC1_SIGNALING+0.400
- DNA_REPAIR+0.380
- OXIDATIVE_PHOSPHORYLATION+0.380
Top 10 suppressed
- MYOGENESIS-0.320
- KRAS_SIGNALING_UP-0.290
- COAGULATION-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- KRAS_SIGNALING_DN-0.230
- BILE_ACID_METABOLISM-0.210
- UV_RESPONSE_DN-0.200
- IL2_STAT5_SIGNALING-0.140
- ESTROGEN_RESPONSE_EARLY-0.120
- TGF_BETA_SIGNALING-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.921 |
| 2 | E0173AAB-678A-46E0-B701-C79A6BE9B9D8 | — | — | 0.913 |
| 3 | DRR168560 | — | — | 0.871 |
| 4 | TCGA-T3-A92N-01A-11R-A39I-07 | — | — | 0.867 |
| 5 | TCGA-A8-A06X-01A-21R-A00Z-07 | — | B | 0.859 |
| 6 | FD76D38B-2A54-4F1A-B7C0-EF268F9D9A0E | — | — | 0.859 |
| 7 | SRR934964 | — | — | 0.856 |
| 8 | SRR650153 | — | — | 0.852 |
| 9 | TCGA-CV-5977-01A-11R-1686-07 | — | — | 0.851 |
| 10 | TCGA-XF-A9T6-01A-11R-A42T-07 | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.740 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.720 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.590 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |